How do you decide between CPX-351 and HMA + Venetoclax in treating transplant eligible AML-MRC?
Answer from: at Community Practice
I would consider CPX-351 (liposomal daunorubicin and cytarabine) in anyone who you would consider to be an induction chemotherapy (7+3) candidate. The indication is for newly diagnosed MDS/AML (AML-MRC) or treatment related MN (t-AML). Benefit is the response can be seen quicker in 1 cycle as oppose...
Sign in or Register to read more